Atorvastatin load for Reduction of MYocardial Damage during Angioplasty of ST-segment Elevation Myocardial Infarction patients.

Trial Profile

Atorvastatin load for Reduction of MYocardial Damage during Angioplasty of ST-segment Elevation Myocardial Infarction patients.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 May 2012

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Myocardial reperfusion injury
  • Focus Therapeutic Use
  • Acronyms ARMYDA-STEMI
  • Most Recent Events

    • 21 May 2012 Planned end date changed from 1 Dec 2012 to 31 Dec 2013 as reported by Chinese Clinical Trial Register.
    • 25 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top